- This topic has 1 reply, 1 voice, and was last updated July 17, 2018 at 6:30 pm by .
- July 17, 2018 at 6:30 pm #387624
Teva Pharmaceuticals USA today confirmed a voluntary recall to the consumer / user level of 29 lots of single and 51 lots of combination valsartan medicines distributed under the Actavis label in the U.S. due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (api) manufactured by zhejiang huahai pharmaceutical. the impurity detected in the api is n- nitrosodimethylamine (ndma), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per international agency for research on cancer (iarc) classification.
This notice provided by Budget101.com
- You must be logged in to reply to this topic.